

سامية محمد مصطفى



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



سامية محمد مصطفى



شبكة المعلومات الجامعية



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



سامية محمد مصطفى



شبكة المعلومات الجامعية

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



سامية محمد مصطفى



شبكة المعلومات الجامعية



بعض الوثائق الأصلية تالفة



سامية محمد مصطفى



شبكة المعلومات الجامعية



بالرسالة صفحات

لم ترد بالأصل





National Cancer Institute
Medical Oncology Department

**A STUDY OF PROGNOSTIC FACTORS IN
ADULTHOOD ACUTE LEUKEMIAS
REVEALED BY SURFACE MARKERS & DNA
ANALYSIS**

Thesis
Submitted For Partial Fulfillment of
The M.D Degree
In
Medical Oncology

BY

Maha Ibrahim Ismael Ibrahim
(M.B.B.Ch/MSC).

Supervisors

Prof. Dr.

Mostafa Mahmoud El-Serafy
Professor & Head of Medical
Oncology Department
NCI, Cairo University

Prof. Dr.

Sameh Sayed Ahmed Shamaa
Professor and Head of Medical
Oncology Department
Mansoura University

Prof. Dr.

Farida Hassan Abdel Rahman
Professor of Clinical Pathology
NCI, Cairo University

2001

B
1CC70

F
(Signature)





فَالرَّوَّاسِبُونَ سَبَّحْنَكَ لَعَلَّ عِلْمَ لَنَا الْإِلَهَ مَا عَلَّمْتَنَا
أَنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

بِسْمِ اللَّهِ
الْعَظِيمِ

سورة البقرة الآية (٢٢)



ACKNOWLEDGMENT

Thanks for God for pleasing this work until it has reached its end as a little part of his generous help throughout our life.

I would like to express my deepest gratitude to my main supervisor

Prof. Dr. Mostafa Mahmoud El-Serafy, Prof. of Medical Oncology and chairman of Medical Oncology Dept, NCI, Cairo University for his support, guidance and stimulation throughout this work.


I am also grateful to **Prof. Dr. Sameh Sayed Ahmed Shamaa**, Prof. of Medical Oncology, internal Medicine, and head of Oncology center, Mansoura University, for his support.

I would like to express my sincere thanks and gratitude to **Prof. Dr. Farida Hassan Abdel Rahman**, Prof. of Clinical Pathology, NCI, Cairo University, for her constant guidance and valuable directions and encouragement.

I would like to express my great thanks to **Prof. Dr. Azza Kamel**, Prof. of Clinical Pathology, NCI, Cairo University for her great valuable directions to me. I must not forget **Dr. Nahla EL-Sharkawy**, Lecturer of clinical pathology, NCI, Cairo University, for her great support to me.

Maha Ibrahim Ismael Ibrahim

2001



CONTENTS

| Subject | Page |
|---|------------|
| Introduction and Aim of Work | 1 |
| Review of Literature | 4 |
| • Pathogenesis of acute leukemias | 4 |
| • Diagnostic evaluation of the patient with acute leukemia. | 5 |
| • Classification of acute leukemia. | 8 |
| • Acute myeloid leukemia. | 16 |
| • Incidence of aetiology of AML. | 16 |
| • Clinical manifestation of AML. | 22 |
| • Diagnosis of AML. | 27 |
| • Treatment of AML. | 36 |
| • Acute lymphatic leukemia. | 58 |
| • Classification of ALL. | 59 |
| • Diagnosis of ALL. | 72 |
| • Treatment of ALL. | 74 |
| • Prognostic factors in acute leukemias. | 101 |
| 1- Immunophenotyping in acute leukemias. | 102 |
| 2- Molecular aspects of acute leukemia. | 116 |
| a) Cell cycle regulation. | 116 |
| b) Cancer genes (oncogenes and tumor suppressor genes). | 119 |
| c) Apoptosis and its regulation. | 122 |
| • P53 biology. | 126 |
| • Bcl-2. | 131 |
| 3- DNA study in acute leukemias. | 140 |
| a) Cytogenetics in acute leukemias. | 140 |
| b) DNA content. | 153 |
| 4- Other prognostic factors in AML. | 156 |
| 5- Other prognostic factors in ALL. | 165 |
| 6- Mechanisms of drug resistance. | 174 |
| Patients and Methods | 184 |
| Results | 190 |
| Discussion | 215 |
| Summary and Recommendations | 230 |
| References | 233 |
| Arabic Summary | |



TABLES IN THE REVIEW SHOW

| | Page |
|--|-------------|
| Morphologic, cytochemical and biochemical characteristics helpful in distinguishing ALL from AML. | 7 |
| Blast types in acute leukemia. | 9 |
| Classification and incidence of subtypes of AML. | 9 |
| FAB classification of acute lymphocytic leukemia. | 10 |
| Cytological criteria for the diagnosis of acute myeloid leukaemia: French-American-British classification. | 15 |
| Correlation between morphologic subtypes of AML and recurring chromosomal translocations. | 21 |
| Cytochemical stains in acute leukemia. | 30 |
| Monoclonal antibodies commonly used to distinguish AML from ALL. | 32 |
| Immunophenotyping markers in AL. | 34 |
| Randomized comparisons of maintenance versus no maintenance in patients in first remission. | 42 |
| Randomized comparison of standard dose ara-C with high dose ara-C in newly diagnosed AML. | 45 |
| Comparison of autologous marrow transplant with chemotherapy or allogeneic marrow transplant in first CR. | 50 |
| Does GM- or G-CSF reduce morbidity or mortality after induction therapy? Results of randomized trials. | 55 |
| Scoring system for L1 and L2 FAB subclasses of ALL. | 60 |
| Cytochemistry of ALL. | 61 |
| Immunologic classification of T-ALL. | 69 |
| Monoclonal antibodies commonly used to immunophenotype leukemia. | 71 |
| Induction therapy of ALL according to the GMALL protocol. | 77 |
| Overall treatment results in adult acute lymphocytic leukemia in larger studies. | 85 |
| Autologous BMT for ALL in first remission. | 92 |
| Randomized study of BMT in first complete remission: long term confirmation of early data. | 94 |
| Clusters of differentiation (CD) antigens useful in the immunologic classification of acute leukemias. | 104 |
| Immunological classification of ALL. | 110 |
| Immunophenotype according to FAB classification in AML. | 111 |
| Recurring chromosome abnormalities in malignant myeloid diseases. | 148 |
| Cytogenetic immunophenotypic correlations in ALL. | 152 |

| | |
|--|-----|
| Unfavorable prognostic factors for outcome of chemotherapy in adult patients with AML. | 157 |
| Prognostic factors in AML. | 162 |
| Established prognostic factors for response to standard chemotherapy in newly diagnosed AML. | 164 |
| Prognostic parameters in ALL at presentation. | 173 |
| Effect of MDR1/Pgp expression on CR. | 177 |
| Characteristics of three mechanisms of multidrug resistance that result from overexpression of P-Glycoprotein (PGP), multidrug resistance associated protein (MRP) or lung resistance related protein (LRP). | 183 |